{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-25-000143","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2025-01-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.811271+00:00","generated_at":"2026-05-27T23:31:47.323120+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Silexion Therapeutics prices ~$5M public offering of shares and warrants at $1.35/unit","bullets":["Gross proceeds expected ~$5M; net proceeds ~$4.26M after placement agent fees and expenses.","Offering includes 3,703,703 ordinary shares (or pre-funded warrants) and identical number of warrants exercisable at $1.35 for 5 years.","Closing expected January 17, 2025; placement agent H.C. Wainwright & Co. receives 7% cash fee plus 1% management fee.","Proceeds to advance pre-clinical studies for KRAS-driven cancer RNAi therapies and for general corporate purposes."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-25-000143","json":"https://secwatch.observer/filing/0001178913-25-000143.json","markdown":"https://secwatch.observer/filing/0001178913-25-000143.md","text":"https://secwatch.observer/filing/0001178913-25-000143.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325000143/0001178913-25-000143-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325000143/zk2532563.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T23:31:47.323120+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}